Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Receivables (2016 - 2025)

Sangamo Therapeutics has reported Receivables over the past 16 years, most recently at $400000.0 for Q4 2025.

  • Quarterly results put Receivables at $400000.0 for Q4 2025, down 91.35% from a year ago — trailing twelve months through Dec 2025 was $400000.0 (down 91.35% YoY), and the annual figure for FY2025 was $400000.0, down 91.35%.
  • Receivables for Q4 2025 was $400000.0 at Sangamo Therapeutics, down from $523000.0 in the prior quarter.
  • Over the last five years, Receivables for SGMO hit a ceiling of $20.5 million in Q3 2024 and a floor of $366000.0 in Q1 2025.
  • Median Receivables over the past 5 years was $4.8 million (2022), compared with a mean of $5.5 million.
  • Biggest five-year swings in Receivables: surged 1071.2% in 2024 and later tumbled 97.45% in 2025.
  • Sangamo Therapeutics' Receivables stood at $6.4 million in 2021, then dropped by 29.36% to $4.5 million in 2022, then tumbled by 70.49% to $1.3 million in 2023, then skyrocketed by 248.87% to $4.6 million in 2024, then plummeted by 91.35% to $400000.0 in 2025.
  • The last three reported values for Receivables were $400000.0 (Q4 2025), $523000.0 (Q3 2025), and $372000.0 (Q2 2025) per Business Quant data.